Mice Model Technologies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (CRISPR Knockout, Random Insertions, Large and Targeted Insertions, ES Cell Modification (Homologous Recombination), Others), By End Users (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Facilities, Contract Research And Manufacturing Organizations), By Region, By Competition, 2020-2030F

Market Overview

The Global Mice Model Technologies Market, valued at USD 1.35 Billion in 2024, is projected to experience a CAGR of 10.30% to reach USD 2.43 Billion by 2030. Mice model technologies encompass the development, production, and application of genetically modified or inbred mouse strains as *in vivo* tools for biomedical research, drug discovery, and toxicology studies. Key drivers supporting this market's growth include increasing research and development investments within the pharmaceutical and biotechnology sectors, the rising demand for personalized medicine approaches, and continuous advancements in genetic engineering techniques such as CRISPR/Cas9, which enable more precise disease modeling.

However, a significant challenge impeding market expansion involves the stringent ethical considerations and regulatory frameworks governing animal welfare in research. According to the Canadian Council on Animal Care, in 2023, mice constituted 36.8% of the 3,128,943 animals utilized across CCAC-certified institutions for research, teaching, and testing purposes.

Key Market Drivers

The escalating global prevalence of chronic diseases acts as a primary catalyst for growth within the mice model technologies market. Conditions such as cancer, diabetes, and neurological disorders necessitate extensive research to elucidate pathogenesis, identify therapeutic targets, and develop effective treatments. Mice models are indispensable tools, providing physiologically relevant *in vivo* systems for disease modeling and drug efficacy testing. The increased burden of these diseases drives demand for specialized mouse models that accurately recapitulate human disease phenotypes. For instance, according to the National Cancer Institute, in an article dated April 4, 2024, "Fiscal Year 2024 Appropriation - NCI", the total appropriation for NCI in fiscal year 2024 was $7.22 billion for cancer research, fueling the application of advanced mouse models crucial for oncology investigations.

Simultaneously, advancements in genetic engineering and gene-editing technologies, notably CRISPR/Cas9, profoundly influence the mice model landscape. These technologies enable precise creation of genetically modified mouse strains with specific gene alterations, allowing for highly accurate disease models and the study of gene function. The ability to rapidly and precisely engineer genetic changes significantly enhances the utility and throughput of mouse models in drug discovery and development. According to a news release from Intellia Therapeutics, dated February 22, 2024, "Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress", their research and development expenses for the full year 2023 reached $508.8 million, largely driven by advancements in their *in vivo* gene-editing programs. Moreover, according to the American Society of Hematology, in an article published October 14, 2025, "ASH Responds to NIH Funding Uncertainty With New Resource Hub", the National Institutes of Health experienced a budget cut of less than 1% overall in its fiscal year 2024 appropriations. These technological strides, coupled with the overarching investment landscape, reinforce the foundational role of mice model technologies in biomedical innovation.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the growth of the Global Mice Model Technologies Market is the stringent ethical considerations and regulatory frameworks governing animal welfare in research. These frameworks impose substantial administrative burdens and increased operational costs on research institutions and pharmaceutical companies involved in developing and utilizing mouse models. Navigating complex approval processes for animal studies can extend timelines for drug discovery and toxicology assessments, thereby slowing the development and application of new mouse models. Furthermore, heightened public and regulatory scrutiny often leads to a reduction in the overall number of animal experiments conducted. According to the European Animal Research Association (EARA), the EU observed a 10% decrease in the use of rats and mice for scientific purposes over the five years leading up to 2022. This declining trend directly limits the potential market for new and existing mice model technologies, as fewer approved studies translate to reduced demand for these specialized research tools. The extensive compliance requirements and ethical debates necessitate significant investments in animal care and oversight, diverting resources that could otherwise be allocated to expanding advanced mice model development and production.

Key Market Trends

Here are two significant trends driving growth in the Global Mice Model Technologies Market:

The increasing development of humanized mice models is a significant trend, driven by the need for preclinical tools that more closely mimic human physiology and disease. These models enhance the translational relevance of drug discovery and development, especially in oncology, immunology, and infectious diseases. Charles River Laboratories, in December 2023, highlighted advancements in next-generation humanized models through CRISPR-mediated genetic modification, expanding their utility for immuno-oncology research. This continuous refinement improves predictive validity and accelerates therapeutic strategies. Researchers at the La Jolla Institute for Immunology, for instance, developed six new lines of humanized mice in October 2024, specifically for investigating human COVID-19 instances.

The emergence of 3D bioprinting for model development is a transformative trend, enabling the creation of complex *in vitro* and *ex vivo* tissue and organ constructs. This technology precisely deposits living cells and biomaterials, replicating native tissue architecture and function. It offers enhanced platforms for drug screening, toxicology, and personalized medicine, potentially reducing reliance on traditional animal models. In March 2024, the US government's Advanced Research Projects Agency for Health (ARPA-H) earmarked USD 65 million for its PRINT program, supporting bioprinted liver, kidney, and heart constructs. This investment accelerates functional organ model creation, with practical applications seen in University Hospital Basel's March 2025 report of the world's first point-of-care facial implant created via 3D bioprinting.

Segmental Insights

The CRISPR Knockout segment is experiencing rapid growth in the Global Mice Model Technologies Market due to its enhanced efficiency, precision, and accelerated model generation capabilities. This technology enables researchers to create specific genetic modifications with high accuracy, significantly reducing the time and cost associated with developing knockout mouse models compared to traditional methods. The simplicity and versatility of CRISPR-Cas9 facilitate simultaneous targeting of multiple genes, which is crucial for intricate genetic studies and the development of more accurate disease models. These advancements are pivotal in accelerating drug discovery and disease research, particularly in areas requiring tailored disease models for personalized medicine initiatives.

Regional Insights

North America leads the global mice model technologies market due to its robust biomedical research infrastructure and substantial investments in pharmaceutical and biotechnology research and development activities. The region's dominance is further driven by the high prevalence of chronic diseases, which necessitates extensive preclinical studies and drug discovery efforts using advanced mice models. Key factors include significant advancements in genetic engineering tools, increasing demand for personalized medicine, and the strong presence of leading research institutions, contract research organizations, and biotechnology companies. This environment, supported by a consistent regulatory framework, fosters continuous innovation and adoption of sophisticated mice model technologies.

Recent Developments

• In July 2025, The Jackson Laboratory announced breakthrough research with the development of novel mouse models for Alternating Hemiplegia of Childhood (AHC), a rare neurological disorder. These new models overcome previous challenges with animal fragility and mortality, enabling preclinical testing for AHC, for which no treatment currently exists. The research provides critical insights into how specific mutations drive neurological disease progression, setting the foundation for developing and applying next-generation gene-editing therapies. This advancement allows for a more accurate understanding of the disorder and accelerates the pace of therapeutic development.

• In June 2025, Taconic Biosciences formed an exclusive license agreement with Helmholtz Munich, a prominent German biomedical research center. This collaboration grants Taconic exclusive rights to a patented CRISPR-based gene editing technology, enhancing its ability to generate genetically modified animal models. The technology is set to significantly improve Taconic's ExpressMODEL® platform, enabling the delivery of high-quality, precise CRISPR/Cas9-generated custom animal models on an accelerated timeline. This partnership strengthens Taconic's leadership in advanced gene-modification methodologies for preclinical research.

• In May 2025, Charles River Laboratories and the CHDI Foundation extended their longstanding collaboration to advance drug discovery for Huntington's disease. This partnership, which began in 2005, leverages specialized Huntington's disease models in preclinical studies. The expanded agreement aims for deeper integration of Charles River's scientific expertise and broader utilization of preclinical models across its global research network. This collaboration reinforces the commitment to developing new therapies for Huntington's disease, highlighting the critical role of mice models in complex neurodegenerative disorder research and therapeutic development.

• In September 2024, Taconic Biosciences introduced its FcResolv® NOG Portfolio, which received a Novel Product Award at the Merck Technology Symposium. These super immunodeficient mouse models are engineered to lack residual murine Fc gamma receptors, which commonly interfere with results in antibody-based therapy studies. Developed in collaboration with the Central Institute for Experimental Medicine and Life Science (CIEM) in Japan, this platform significantly enhances the accuracy of efficacy studies for therapies incorporating an Fc domain. The models are valuable for research across immuno-oncology, autoimmune diseases, and infectious diseases by providing clearer preclinical assessment of drug candidates.

Key Market Players

• Biocytogen LLC
• Charles River Laboratories Inc.
• Cyagen Biosciences
• GemPharmatech Co Ltd.
• genOway S.A.
• Ingenious Targeting Laboratory Inc.
• Merck KGaA.
• Ozgene Pty Ltd.
• Taconic Biosciences Inc.
• Polygena AG

Report Scope:

In this report, the Global Mice Model Technologies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Mice Model Technologies Market, By Technology:

o   CRISPR Knockout

o   Random Insertions

o   Large and Targeted Insertions

o   ES Cell Modification (Homologous Recombination)

o   Others

• Mice Model Technologies Market, By End Users:

o   Pharmaceutical Companies

o   Biotechnology Companies

o   Academic and Research Facilities

o   Contract Research and Manufacturing Organizations

• Mice Model Technologies Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Mice Model Technologies Market.

Available Customizations:

Global Mice Model Technologies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Mice Model Technologies Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]